Makary to Resign as FDA Commissioner

Food and Drug Administration (FDA) Commissioner Marty Makary (R) will Announce His Resignation on 5/12/2026, amid mounting Reports of Trump’s (R) growing Dissatisfaction with the Physician’s Tenure. Makary to be Replaced by Kyle Diamantas (R), who will serve as Acting Director.

Trump Speaking to Reporters on 5/12/2026 ahead of His trip to China, Declined to say whether He asked Makary to Resign or whether He Fired Hhim.

“Well, I don’t want to say, but Marty’s a great guy, he’s a friend of mine, he’s a wonderful man and he’s going to be off. And the assistant, the deputy, is taking over temporarily until we find — everybody wants that job. It’s a very important job,” said Trump. “Marty’s a terrific guy but he’s going to go on and he’s going to lead a good life,” He added. “He was having some difficulty. You know, he’s a great doctor and he was having some difficulty.”

Makary’s Departure marks the Third Senate-Confirmed Trump Administration Official to Leave their Role this year. It also comes shortly after Trump Pulled His Nomination of Casey Means for Surgeon General.

Makary’s Resignation wasSspurred by Conflicts surrounding Flavored Vapes, which the Commissioner did Not want to Approve. The FDA Granted Marketing Authorization for Four New Products last Week.

Makary has Served in the Administration for just over a Year. His time atop FDA has been Marked by Departures of several High-Level Officials, Internal Administrative Clashes, Demoralized Staff, and Complaints from the Pharmaceutical Industry.

The Wall Street Journal was First to Report on Trump’s Plans to Remove Makary. Last month, the Outlet Reported that Trump Reprimanded Makary for Refusing to Authorize New Flavored Vape Products.

Makary has also Angered Anti-Abortion Lawmakers, Who want Him to be more Aggressive in Restricting Access to the Abortion Pill Mifepristone. Leading Anti-Abortion Groups had called for His Firing.

Sen. Bill Cassidy (R-LA), Chair of the Senate Committee on Health, Education, Labor, and Pensions, Lambasted Makary, after the FDA Approved a Second Generic Abortion Pill last year, and Expressed Frustration with His Agency seemingly Delaying a Promised Safety Review of the Drug.

Trump Denied having any Knowledge of Makary’s Imminent Departure over the Weekend, telling Reporters, “I’ve been reading about it, but I know nothing about it,” when Asked about the FDA Head’s Termination.

Makary had been Scheduled to Testify before a Senate Appropriations Subcommittee on 5/13/2026, to Discuss the FDA Budget.










NYC Wins When Everyone Can Vote! Michael H. Drucker